The Schwab U.S. Dividend Equity ETF ( SCHD ) Offers a Higher Yield and Lower Cost Than the iShares Core High Dividend ETF ( HDV )
The iShares Core High Dividend ETF ( NYSEMKT:HDV ) and the Schwab U.S. Dividend Equity ETF ( NYSEMKT:SCHD ) both focus on U.S. dividend stocks, but SCHD stands out for its lower cost, higher yield, and much larger assets under management, while HDV has shown stronger recent returns.Both the ...
Amgen EVP Sold $2.32M In Company Stock - Amgen ( NASDAQ:AMGN )
Murdo Gordon, EVP at Amgen ( NASDAQ:AMGN ) , executed a substantial insider sell on November 14, according to an SEC filing. What Happened: According to a Form 4 filing with the U.S. Securities and Exchange Commission on Friday, Gordon sold 6,879 shares of Amgen. The total transaction value ...
Sell Alert: Rachna Khosla Cashes Out $299K In Amgen Stock - Amgen ( NASDAQ:AMGN )
A substantial insider sell was reported on November 14, by Rachna Khosla, SVP at Amgen ( NASDAQ:AMGN ) , based on the recent SEC filing. What Happened: Khosla's recent move involves selling 890 shares of Amgen. This information is documented in a Form 4 filing with the U.S.
Can Lilly's Next-Gen Obesity Drugs Help Sustain Its Market Dominance?
Eli Lilly's next-gen obesity drugs, led by oral orforglipron and triple-acting retatrutide, aim to reshape the fast-growing weight-loss market.
Why Amgen Stock Edged Past the Market on Thursday
The pharmaceutical sector mainstay earned several positive mentions in the pundit sphere that day.
2 Supercharged Dividend Stocks to Buy Now
Innovative drugmakers often make for solid dividend stocks. These two companies are great examples.
A Closer Look at Amgen's Options Market Dynamics - Amgen ( NASDAQ:AMGN )
High-rolling investors have positioned themselves bullish on Amgen ( NASDAQ:AMGN ) , and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's tracking of publicly available options data.
Is the Schwab U.S. Dividend Equity ETF the "Ultimate Retirement Fund" for Investors?
A $10,000 investment in this diversified fund at its 2011 inception would be worth $51,000 today.
Alvotech Reports Results for the First Nine Months of 2025 and Provides a Business Update
REYKJAVIK, Iceland, November 12, 2025 - Alvotech ( NASDAQ: ALVO, or the "Company" ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported financial results for the first nine months of 2025 and provided a summary ...
Alvotech Reports Results for the First Nine Months of 2025 and Provides a Business Update
REYKJAVIK, Iceland, Nov. 12, 2025 ( GLOBE NEWSWIRE ) -- Alvotech ( NASDAQ: ALVO, or the "Company" ) , a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported financial results for the first nine months of 2025 and ...
Why Amgen Stock Was a Nearly 5% Winner Today
The company continued to bask in the glow of a very solid third quarter.
Three Healthcare Buys That Wall Street Loves
These three healthcare stocks are outperforming most of the sector.
Amgen Inc. ( AMGN ) Is a Trending Stock: Facts to Know Before Betting on It
Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Beat the Market the Zacks Way: Amgen, Ciena, Fair Isaac in Focus
Amgen, Ciena, and Fair Isaac shine as Zacks' proven stock-ranking strategies continue to outperform amid market uncertainty.
Is the Schwab U.S. Dividend Equity ETF a Buy Now?
Not every investor will like this exchange-traded fund. But many will.
Amgen: Will Stock Reverse Again? A Technical Analysis - Amgen ( NASDAQ:AMGN )
Amgen Inc. ( NASDAQ:AMGN ) is lower on Thursday. Yesterday, the shares gained almost 8% after the company released earnings. The firm has reached a critical price level. This is why it is our Stock of the Day. If a stock is in an uptrend, it is due to an imbalance in demand and supply.
Company News for Nov 6, 2025
Companies In The News Are: AMGN, EXEL, LITE, MCD.
Why Amgen Stock Was Crushing It on Wednesday
Its latest quarterly results were solid, thanks to strong sales of its top products.
Amgen's Q3 Earnings & Sales Beat, 2025 Outlook Raised, Stock Up
AMGN's Q3 earnings and revenues top estimates as key drugs drive double-digit growth. The company also raises its 2025 outlook.
Markets Stay Lower on Valuation Questions: AI, etc.
We've entered the rapid-pace phase of Q3 earnings season, where results tend to come in more blended than they do for the earlier-reporting sectors.
Amgen ( AMGN ) Q3 Earnings and Revenues Beat Estimates
Amgen (AMGN) delivered earnings and revenue surprises of +12.80% and +6.87%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
3 Top Dividend Stocks to Maximize Your Retirement Income
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
Does the Market Have Bad Breadth?
Is the breadth in this market, or lack thereof, a sign of weakening trading sentiment?
Novo Nordisk Before Q3 Earnings: How Should Investors Play the Stock?
NVO faces slowing Wegovy and Ozempic momentum, pricing risks and fierce competition ahead of Q3 earnings.
You Won't Believe What Elon Musk Just Said About Quantum Computing ( Spoiler Alert: It's Good News )
Elon Musk had some encouraging thoughts following Alphabet's latest quantum breakthrough.
Demographic Megatrend: Stocks Poised to Benefit From Global Aging
Global aging is reshaping healthcare demand. Discover how AbbVie, Amgen, Boston Scientific and Edwards are positioned to gain from this powerful megatrend.
A Look Into Amgen Inc's Price Over Earnings - Amgen ( NASDAQ:AMGN )
In the current session, Amgen Inc. ( NASDAQ:AMGN ) is trading at $291.80, after a 0.07% drop. Over the past month, the stock fell by 2.04%, and in the past year, by 7.92%. With performance like this, long-term shareholders are more likely to start looking into the company's price-to-earnings ...
Investors Heavily Search Amgen Inc. ( AMGN ) : Here is What You Need to Know
Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Marjorie Taylor Greene Buys Netflix Stock After Downbeat Q3 Earnings, Expands Big Tech Bet - Netflix ( NASDAQ:NFLX )
Rep. Marjorie Taylor Greene ( R-Ga. ) purchased Netflix Inc. on Oct.24, just days after the streaming giant's stock tumbled following a disappointing third-quarter earnings report. The purchase, valued between $1,001 and $15,000, was one of 14 new investments disclosed in a Periodic ...
Amgen ( AMGN ) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
Get a deeper insight into the potential performance of Amgen (AMGN) for the quarter ended September 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
Amgen's Q3 Earnings in the Cards: Here's What to Expect
Amgen's Q3 results are on deck, with growth from newer drugs offset by biosimilar competition and pricing pressures.
Analysts Estimate Acadia Pharmaceuticals ( ACAD ) to Report a Decline in Earnings: What to Look Out for
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Amgen ( AMGN ) Q3 Earnings Expected to Decline
Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What Does the Market Think About Amgen Inc? - Amgen ( NASDAQ:AMGN )
Amgen Inc's ( NYSE:AMGN ) short interest as a percent of float has fallen 11.2% since its last report. According to exchange reported data, there are now 11.48 million shares sold short, which is 2.14% of all regular shares that are available for trading.
Biogen's Immunology Pipeline Has Long-Term Potential: Analyst - Biogen ( NASDAQ:BIIB )
On Friday, Biogen Inc. ( NASDAQ:BIIB ) and Vanqua Bio announced a license agreement granting Biogen exclusive worldwide rights to Vanqua's preclinical, oral C5aR1 antagonist. The agreement strengthens Biogen's immunology.
The Zacks Analyst Blog Highlights Amazon.com, Wells Fargo, Amgen, IDT and Village Super Market
Zacks spotlights Amazon, Wells Fargo, Amgen, IDT and Village Super Market in its latest Analyst Blog, showcasing diverse growth drivers and risks.
1 Top Dividend Growth Stock to Buy Right Now
Its shares might not remain undervalued for that much longer.
Amgen ( AMGN ) Stock Sinks As Market Gains: What You Should Know
Amgen (AMGN) closed at $292.89 in the latest trading session, marking a -1.04% move from the prior day.
Top Research Reports for Amazon.com, Wells Fargo & Amgen
Amazon's AI push, Wells Fargo's post-cap growth, and Amgen's new drug momentum headline Zacks' latest top analyst reports.
Why Amgen ( AMGN ) Dipped More Than Broader Market Today
The latest trading day saw Amgen (AMGN) settling at $295.98, representing a -1.71% change from its previous close.
Johnson & Johnson Targets Accelerated Growth Across Segments in 2026
J&J projects faster 2026 growth in Innovative Medicine and MedTech, topping consensus estimates on both revenues and EPS.
Here is What to Know Beyond Why Amgen Inc. ( AMGN ) is a Trending Stock
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Is iShares Biotechnology ETF ( IBB ) a Strong ETF Right Now?
Smart Beta ETF report for ...
Price Over Earnings Overview: Amgen - Amgen ( NASDAQ:AMGN )
In the current market session, Amgen Inc. ( NASDAQ:AMGN ) share price is at $295.58, after a 0.08% drop. Over the past month, the stock increased by 3.56%, but over the past year, it actually fell by 6.68%.
Novo, Lilly, Pfizer: Who Wins If Trump Slashes Prices? - Novo Nordisk ( NYSE:NVO ) , Eli Lilly ( NYSE:LLY ) , Pfizer ( NYSE:PFE )
President Donald Trump just dropped a political bomb into one of Wall Street's hottest trades.
The Zacks Analyst Blog Highlights Eli Lilly, Novo Nordisk, Amgen and Viking Therapeutics
Eli Lilly's blockbuster GLP-1 drugs, Mounjaro and Zepbound, are driving explosive growth as the company prepares to report Q3 results.
Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity - Climb Bio ( NASDAQ:CLYM )
William Blair initiated coverage for Climb Bio ( NASDAQ:CLYM ) , citing the potential of the company's budoprutug, under development for autoimmune indications, including: Phase 1b/2a immune thrombocytopenia ( ITP ) trial FPI achieved, enrollment ongoing.
How Will Mounjaro and Zepbound Sales Aid Lilly's Upcoming Q3 Results?
Strong demand for Mounjaro and Zepbound is expected to power LLY's Q3 growth, as both drugs deepen U.S. and global market reach.
Amgen ( AMGN ) Laps the Stock Market: Here's Why
In the closing of the recent trading day, Amgen (AMGN) stood at $297.32, denoting a +1.18% move from the preceding trading day.
JNJ Beats on Q3 Earnings, Ups Sales View, to Spin-off Orthopaedics Unit
J&J tops Q3 forecasts, lifts 2025 sales outlook and plans to spin off its struggling Orthopaedics business.
